• Qiqi Jiang, Peizhen Geng, Yuying Zhang, Maoquan Yang, Jiafeng Zhu, Mingwei Zhang, Yamei Wang, Yikuan Feng, and Xiaojuan Sun.
• Department of Gastroenterology, Weifang People's Hospital, The First Affiliated Hospital of Weifang Medical University, Weifang, Shandong, China.
• Medicine (Baltimore). 2024 Jun 7; 103 (23): e38244e38244.

BackgroundNumerous studies have investigated the association between CDH1 polymorphisms and gastric cancer (GC) risk. However, the results have been inconsistent and controversial. To further determine whether CDH1 polymorphisms increase the risk of GC, we conducted a meta-analysis by pooling the data.MethodsRelevant case-control studies were collected from PubMed, Embase, Web of Science and Cochrane databases up to January 7, 2024. Subsequently, odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of correlations. A sensitivity analysis was performed to evaluate the robustness and reliability of these included studies.ResultsA total of 25 articles including 44 studies, were included in this meta-analysis, including 26 studies on rs16260, 6 studies on rs3743674, 7 studies on rs5030625, and 5 studies on rs1801552. The pooled results showed that rs16260 was remarkably associated with an increased GC risk of GC among Caucasians. Moreover, the rs5030625 variation dramatically enhanced GC predisposition in the Asian population. However, no evident correlations between CDH1 rs3743674 and rs1801552 polymorphisms and GC risk were observed.ConclusionsOur findings suggested that CDH1 gene polymorphisms were significantly correlated with GC risk, especially in rs16260 and rs5030625 polymorphisms.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

17 keywords...

hide…